# Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)

> **NCT00126321** · PHASE2 · UNKNOWN · sponsor: **University Hospital, Bonn** · enrollment: 50 (estimated)

## Conditions studied

- Leukemia, Myelocytic, Acute

## Interventions

- **DRUG:** cladribine

## Key facts

- **NCT ID:** NCT00126321
- **Lead sponsor:** University Hospital, Bonn
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-11
- **Primary completion:** 2010-11
- **Final completion:** 2011-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2010-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126321, "Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00126321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*